Interesting! I am inclined to consider the possibility that this may not be preclinical testing but instead a deliberate attempt by CYP to set themselves up for a takeover offer by an animal therapeutics company.
Consider the following: 1) CYP treats and cures heart disease in rats and 2) CYP obtains a label extension to treat heart disease in cats and dogs.
If you think about it there are literally billions of rats, cats and dogs in the world and CYP has superior manufacturing capabilities where one donor can create 30 million treatment doses. No wonder why Sector is so confident in CYP.
MESOBLAST- FUNDAMENTALS discussions, page-214
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.48 |
Change
0.105(7.64%) |
Mkt cap ! $1.689B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.49 | $1.38 | $8.181M | 5.685M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25443 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 60811 | 4 |
View Market Depth
| Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |